29.05
price up icon2.80%   0.79
after-market Dopo l'orario di chiusura: 29.05
loading

Alkermes Plc Borsa (ALKS) Ultime notizie

pulisher
Aug 15, 2025

Investors Don't See Light At End Of Alkermes Plc's (NASDAQ:ALKS) Tunnel - 富途牛牛

Aug 15, 2025
pulisher
Aug 15, 2025

Is Alkermes plc stock influenced by commodity prices2025 Trading Volume Trends & Pattern Based Trade Signal System - thegnnews.com

Aug 15, 2025
pulisher
Aug 12, 2025

Live Scanner Shows Breakout on Alkermes plcMarket Surge Signal for Swing Traders Triggered - metal.it

Aug 12, 2025
pulisher
Aug 10, 2025

Is Alkermes plc in a long term uptrendWealth Leverage Stock List - mustnews.co.kr

Aug 10, 2025
pulisher
Aug 08, 2025

BlackRock increases stake in Alkermes to 17% - Investing.com India

Aug 08, 2025
pulisher
Aug 08, 2025

BlackRock increases stake in Alkermes to 17% By Investing.com - Investing.com Nigeria

Aug 08, 2025
pulisher
Aug 04, 2025

Alkermes plc Included in Top Momentum ScanInvestment Strategy Designed for Capital Protection - metal.it

Aug 04, 2025
pulisher
Aug 04, 2025

Chondrosarcoma Market: Epidemiology, Pipeline Products, - openPR.com

Aug 04, 2025
pulisher
Aug 04, 2025

Alkermes plc Announces Pricing of New Term Loans - AOL.com

Aug 04, 2025
pulisher
Aug 03, 2025

What markets is AAON Inc. expanding into Is Alkermes plc stock a good long term investment optionBuild a diversified portfolio for steady growth - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What is the dividend policy of Alkermes plc stockUnmatched market gains - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Is Alkermes plc a growth stock or a value stockInvest smarter with expert trading signals - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What makes Alkermes plc stock price move sharplyInvest confidently with professional advice - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Is Alkermes plc stock overvalued or undervaluedGet exclusive access to expert stock recommendations - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Alkermes Q2 Earnings Beat Estimates, Proprietary Drugs Aid Sales - MSN

Aug 03, 2025
pulisher
Aug 03, 2025

What catalysts could drive Alkermes plc stock higher in 2025Invest confidently with professional advice - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Should I hold or sell Alkermes plc stock in 2025Get expert analysis on top stock picks - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Needham & Company LLC Reaffirms "Buy" Rating for Alkermes (NASDAQ:ALKS) - MarketBeat

Aug 03, 2025
pulisher
Aug 03, 2025

How does Alkermes plc generate profit in a changing economyBuild capital through low-risk investments - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What are analysts’ price targets for Alkermes plc in the next 12 monthsAchieve rapid portfolio growth with expert guidance - Jammu Links News

Aug 03, 2025
pulisher
Aug 02, 2025

What are the technical indicators suggesting about Alkermes plcDiscover investment plans that deliver results - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

How strong is Alkermes plc company’s balance sheetUnlock powerful portfolio optimization tools - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

What markets is Alkermes plc expanding into Is ASLE stock a good long term investment optionBuild a portfolio that outperforms consistently - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

Alkermes Reports Q2 2025 Financial Results, Reiterates Expectations and Highlights Positive Clinical Study Results - AInvest

Aug 02, 2025
pulisher
Aug 02, 2025

ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Alkermes plc To Contact The Firm - ACCESS Newswire

Aug 02, 2025
pulisher
Jul 31, 2025

Alkermes shares climb 5% following Q2 earnings and revenue beat - MSN

Jul 31, 2025
pulisher
Jul 31, 2025

(07/31/25) ALKS: Positive Narcolepsy Drug Trial Puts this Biotech Name in F - moneyshow.com

Jul 31, 2025
pulisher
Jul 30, 2025

Alkermes anticipates record proprietary product sales above $1B for 2025 as orexin pipeline advances - MSN

Jul 30, 2025
pulisher
Jul 30, 2025

Alkermes: A More Than Solid Quarter (NASDAQ:ALKS) - Seeking Alpha

Jul 30, 2025
pulisher
Jul 30, 2025

Alkermes stock price target raised to $42 from $40 at RBC Capital - Investing.com Nigeria

Jul 30, 2025
pulisher
Jul 30, 2025

Alkermes plc (NASDAQ:ALKS) Q2 2025 Earnings Call Transcript - Insider Monkey

Jul 30, 2025
pulisher
Jul 30, 2025

Alkermes Beat Expectations With A Strong Second Quarter - Finimize

Jul 30, 2025
pulisher
Jul 30, 2025

Schizophrenia Drugs Market Exclusive Report with Detailed - openPR.com

Jul 30, 2025
pulisher
Jul 30, 2025

Alkermes PLC (ALKS) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada

Jul 30, 2025
pulisher
Jul 30, 2025

Alkermes: Q2 Earnings Snapshot - Norwalk Hour

Jul 30, 2025
pulisher
Jul 29, 2025

Alkermes Reports Strong Q2 2025 Financial Results - TipRanks

Jul 29, 2025
pulisher
Jul 29, 2025

Trading Bots Trigger Alerts on Alkermes plc ActivityDaily Smart Money Movement Monitor Activated - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

Multi Factor Analysis Ranks Alkermes plc as Strong BuyAI Driven Stock Trend Forecast Shows Momentum Shift - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

Alkermes Earnings Call: Strong Growth and Promising Trials - TipRanks

Jul 29, 2025
pulisher
Jul 29, 2025

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Alkermes plc of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 22, 2018ALKS - ACCESS Newswire

Jul 29, 2025
pulisher
Jul 29, 2025

Alkermes price target lowered to $33 from $35 at BofA - TipRanks

Jul 29, 2025
pulisher
Jul 29, 2025

Why Alkermes plc stock attracts strong analyst attentionScalable Portfolio Growth Suggestions Released - metal.it

Jul 29, 2025
$17.96
price down icon 0.22%
drug_manufacturers_specialty_generic RDY
$14.22
price up icon 0.78%
$10.61
price down icon 0.75%
$132.90
price up icon 1.21%
$313.13
price up icon 0.34%
Capitalizzazione:     |  Volume (24 ore):